Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ChulaCov19 mRNA vaccine(Chulalongkorn University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
ChulaCov19 mRNA vaccine(Chulalongkorn University): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP.
8 min read
JKB-122 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
JKB-122: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
TAF-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
TAF-001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Progerinin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Progerinin: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
Latest Hotspot
8 min read
PTK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PTK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTGDR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PTGDR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PRCD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PRCD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PRAME Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PRAME sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PPARGC1A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PPARGC1A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PPARD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PPARD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PNMA5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PNMA5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PNMA3 Biologics Sequence Review Report 2026: Paraneoplastic antigen Ma3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PNMA3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.